These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36864622)

  • 21. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
    Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
    Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.
    Kedor C; Zernicke J; Hagemann A; Gamboa LM; Callhoff J; Burmester GR; Feist E
    Clin Rheumatol; 2016 Sep; 35(9):2203-10. PubMed ID: 27470087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial.
    St Clair EW; Baer AN; Wei C; Noaiseh G; Parke A; Coca A; Utset TO; Genovese MC; Wallace DJ; McNamara J; Boyle K; Keyes-Elstein L; Browning JL; Franchimont N; Smith K; Guthridge JM; Sanz I; James JA;
    Arthritis Rheumatol; 2018 Sep; 70(9):1470-1480. PubMed ID: 29604186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
    Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
    Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tofacitinib in the treatment of primary Sjögren's syndrome-associated interstitial lung disease: study protocol for a prospective, randomized, controlled and open-label trial.
    Gao R; Pu J; Wang Y; Wu Z; Liang Y; Song J; Pan S; Han F; Yang L; Xu X; Tang J; Wang X
    BMC Pulm Med; 2023 Nov; 23(1):473. PubMed ID: 38007449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.
    Gottenberg JE; Ravaud P; Puéchal X; Le Guern V; Sibilia J; Goeb V; Larroche C; Dubost JJ; Rist S; Saraux A; Devauchelle-Pensec V; Morel J; Hayem G; Hatron P; Perdriger A; Sene D; Zarnitsky C; Batouche D; Furlan V; Benessiano J; Perrodeau E; Seror R; Mariette X
    JAMA; 2014 Jul; 312(3):249-58. PubMed ID: 25027140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study.
    Yoon CH; Lee HJ; Lee EY; Lee EB; Lee WW; Kim MK; Wee WR
    J Korean Med Sci; 2016 Jul; 31(7):1127-35. PubMed ID: 27366013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and Application of the Placebo Response Model in Clinical Trials for Primary Sjögren's Syndrome.
    Wang ZZ; Zheng QS; Liu HX; Li LJ
    Front Immunol; 2021; 12():783246. PubMed ID: 34868062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial.
    van der Heijden EHM; Blokland SLM; Hillen MR; Lopes APP; van Vliet-Moret FM; Rosenberg AJWP; Janssen NG; Welsing PMJ; Iannizzotto V; Tao W; Pandit A; Barone F; Kruize AA; Radstake TRDJ; van Roon JAG
    Lancet Rheumatol; 2020 May; 2(5):e260-e269. PubMed ID: 38273473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
    Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
    J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
    Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
    Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral neuropathy and health-related quality of life in patients with primary Sjögren's syndrome: a preliminary report.
    Jaskólska M; Chylińska M; Masiak A; Nowicka-Sauer K; Siemiński M; Ziętkiewicz M; Czuszyńska Z; Zdrojewski Z
    Rheumatol Int; 2020 Aug; 40(8):1267-1274. PubMed ID: 32172462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome.
    Brown S; Navarro Coy N; Pitzalis C; Emery P; Pavitt S; Gray J; Hulme C; Hall F; Busch R; Smith P; Dawson L; Bombardieri M; Wan-Fai N; Pease C; Price E; Sutcliffe N; Woods C; Ruddock S; Everett C; Reynolds C; Skinner E; Poveda-Gallego A; Rout J; Macleod I; Rauz S; Bowman S;
    BMC Musculoskelet Disord; 2014 Jan; 15():21. PubMed ID: 24438039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
    Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
    Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
    Mariette X; Seror R; Quartuccio L; Baron G; Salvin S; Fabris M; Desmoulins F; Nocturne G; Ravaud P; De Vita S
    Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients.
    Jiang W; Zhang L; Zhao Y; He X; Hu C; Liu Y
    Int Ophthalmol; 2020 Nov; 40(11):3059-3065. PubMed ID: 32607949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progenitor cell niche senescence reflects pathology of the parotid salivary gland in primary Sjögren's syndrome.
    Wang X; Bootsma H; Terpstra J; Vissink A; van der Vegt B; Spijkervet FKL; Kroese FGM; Pringle S
    Rheumatology (Oxford); 2020 Oct; 59(10):3003-3013. PubMed ID: 32159757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.